HIV News on Human Trial - ABC 7 Empowering Voices Interview

ABC 7 Sarasota WWSB's Renee James Gilmore Interviews American Gene Technologies CEO Jeff Galvin. In this interview, CEO Jeff Galvin explains American Gene Technologies (AGT)'s HIV cure program and its Phase 1 study of AGT103-T, a genetically modified cell product made from a person's own cells. AGT's approach is unique in that it focuses on repairing the key immune system damage caused by HIV. AGT’s goal is to develop a cell and gene therapy capable of repairing the immune system so it will provide natural control over HIV replication. The AGT103-T clinical trial is being conducted at sites in the Washington, DC metropolitan area starting with the Washington Health Institute in the District of Columbia. More information about participation and trial sites can be found at ClinicalTrials.gov. If you liked this video, please subscribe to our channel here:    / @americangenetechnologies   Learn more about AGT's HIV cure program: https://www.americangene.com/pipeline... About AGT: American Gene Technologies (AGT) is a gene and cell therapy company with a proprietary gene-delivery platform for rapid development of cell and gene therapies to cure infectious diseases, cancers, and inherited disorders. AGT's mission is to transform people's lives through genetic medicines that rid the body of disease. Visit our website and subscribe to our news for updates here: https://www.americangene.com Subscribe to receive our news updates here: https://bit.ly/3ughPNR Follow the company on social media--- Twitter: Jeff - @jeffreygalvin -   / jeffreygalvin   AGT - @americangene -   / americangene   LinkedIn: Jeff -   / jeff-galvin-60258   AGT -   / american-gene-technologies-international-inc   Facebook/Instagram: Facebook -   / amerigene   Instagram -   / americangenetechnologies